ADVANCING PRECISION SGK1 INHIBITORS AT THE INTERSECTION OF ELECTRICAL AND STRUCTURAL HEART DISEASE
San Francisco, California – November 12, 2026 – Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies through its pipeline of potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1), today announced that Paul Truex, Chairman and Chief Executive Officer, will present at the UBS Global Biopharma Conference, taking place November 16–17, 2026, in London, UK.
UBS Global Biopharma Conference 2026
Dates: November 16–17, 2026
Fireside chat: Tuesday, November 17, 2026, at 3:20 pm GMT (10:20 am ET)
Location: London, UK
Format: Fireside chat and one-on-one investor meetings
To request a meeting with Thryv Therapeutics, please contact admin@thryvtrx.com
The company looks forward to updating investors on recent pipeline progress, including:
Closing of a $30 million Series B financing led by InClin, Inc., with continued support from existing investors
Completion of enrollment in the first efficacy cohort of the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome (NCT07277582), with data expected in early 2027
Establishment of clinical operations in Australia ahead of enrollment opening in early 2027 for ASPIRE-HF, a Phase 2a study of THRV-1268 in patients with heart failure with reduced ejection fraction (HFrEF) and QTc prolongation
About Thryv Therapeutics Inc.
Thryv Therapeutics Inc. is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. SGK1 sits at the intersection of electrical and structural heart disease, where electrical instability drives the inflammation and fibrosis that lead to adverse structural remodeling. Thryv’s lead candidate, THRV-1268, is being evaluated in two clinical trials: Wave II, a Phase 2/3 study in patients with Long QT Syndrome Type 2 (LQT2) and Type 3 (LQT3), and ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction (HFrEF). For more information, visit www.thryvtrx.com.
Investor and Media Contact
brittany@thryvtrx.com | 514 973 0915
